ArticleSurgical endoscopy2026
Clinical outcomes of endoscopic balloon dilatation for postoperative anastomotic stricture after distal gastrectomy.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostoperative anastomotic luminal obstruction is a rare but clinically significant complication after distal gastrectomy. Endoscopic balloon dilatation (EBD) is a minimally invasive treatment; however, some patients require additional interventions. This study aimed to evaluate the clinical outcomes of EBD for postoperative anastomotic luminal narrowing and to identify predictors associated with treatment failure.
methodsWe retrospectively reviewed 56 patients who developed anastomotic strictures after distal gastrectomy, and treated with EBD between January 2010 and December 2022 at Asan Medical Center, Seoul, Korea. Clinical data, including patient characteristics, surgical factors, and endoscopic findings, were analyzed. Patients were classified into an EBD-only group and an additional-intervention group (stent insertion or surgery). Univariate and multivariable logistic regression analyses were performed to identify predictors of EBD refractoriness.
resultsOf the 56 patients, 45 (80.3%) achieved symptom improvement with EBD alone, whereas 11 (19.6%) required additional interventions. Diabetes mellitus and failure of scope passage were more frequent in patients who required additional interventions compared with those treated with EBD alone. Multivariable analysis indicated that only failure of scope passage remained an independent predictor (odds ratio, 16.81; 95% confidence interval, 1.61-411.44; p = 0.030). There was one procedure-related complication, aspiration pneumonia, which improved with conservative treatment.
conclusionsEBD is an effective and safe first-line treatment for anastomotic strictures after distal gastrectomy. Failure of scope passage through the anastomosis is a simple yet reliable predictor of EBD refractoriness.
Indexed as
Identifiers
42151461What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.